Effects of Levosimendan Pretreatment in Patients With Low Ejection Fraction (40 % or Less) Undergoing CABG: a Randomised, Double Blind, Multicenter Trial
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2017
Price : $35 *
At a glance
- Drugs Levosimendan (Primary)
- Indications Low cardiac output
- Focus Therapeutic Use
- Acronyms LICORN
- 08 Aug 2017 Primary endpoint (Confirmed low cardiac output syndrome) has not been met, as per results published in the JAMA: the Journal of the American Medical Association.
- 08 Aug 2017 Results published in the JAMA: the Journal of the American Medical Association
- 24 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.